Investments
Commented by Nico Popp on December 15th, 2022 | 10:48 CET
Gold Rally! Why precious metals offer themselves now: Barrick Gold, Tocvan Ventures, Steinhoff
Especially during uncertain stock market times, it pays to keep an eye on various asset classes. One of them, namely gold, has recently delivered the first rally signals. In this article, we outline what this means for investors and why precious metals are not a question of faith. What are the alternatives to gold, and what stocks offer opportunities now?
Read
Commented by Nico Popp on December 14th, 2022 | 11:58 CET
Hydrogen: Where things get tight, where opportunities lurk - NEL, First Hydrogen, Amazon
Hydrogen is picking up speed! In northern Germany, the first hydrogen trains recently went into regular service. At the same time, decision-makers from Spain, France and Portugal are working with the EU on a hydrogen pipeline from Barcelona to Marseille. From 2030, green hydrogen should also flow indirectly through this pipeline to Germany. We present companies that could benefit and are already setting the course for tomorrow.
Read
Commented by Stefan Feulner on December 13th, 2022 | 10:43 CET
Rheinmetall, Aspermont, BioNTech - Strong momentum
With its many drastic events, the turbulent stock market year 2022 is drawing to a close. With the Ukraine war, the change in monetary policy by central banks and rampant inflation, the year was characterized by strong uncertainty and high volatility, and it is almost certain to continue in the coming year. Nevertheless, the favourites are emerging more and more clearly from various sectors that should outperform the broad market in the months ahead.
Read
Commented by Armin Schulz on December 12th, 2022 | 10:20 CET
BioNTech, va-Q-tec, Cardiol Therapeutics, Ambrx Biopharma - Biotech second-line stocks explode
For investors in biotech stocks, 2022 was often a year to forget. After the Corona hype, the market clouded over significantly, in part due to rising interest rates. December is the time of year when investors can make adjustments to their portfolio, thereby reducing their tax burden for the year ahead. This year is no exception, yet three stocks shot up last Friday. That is unusual during tax loss season. We look at the three high flyers and BioNTech, a big player in the biotech sector.
Read
Commented by Juliane Zielonka on December 9th, 2022 | 11:26 CET
Pathfinder Ventures, TUI, PayPal - The travel industry is booming, and crypto is following suit
After two years off, the wait is over! The travel industry is booming, and so are the companies in this segment. Leading the way is Pathfinder Ventures, a Canadian company in the expandable niche of modern nature-recreation resorts for RV lovers and campers. Sales increased by a whopping 19% in Q3 2022 compared to the previous year. Hanover-based TUI AG is also testing other niches. The Company is known for luxury travel and cruises and is striving for new target groups in the low-budget segment. Together with easyJet Holidays, they are rolling out a digital experience platform for experiences at vacation destinations. To be fluid wherever they go, many use the PayPal payment service. The US company is now rolling out cryptocurrencies in Luxembourg. Read what exactly this means for investors here.
Read
Commented by Fabian Lorenz on December 8th, 2022 | 09:09 CET
Shares: Buy FlatexDegiro now? Uniper gambles, Aspermont before multiplication and Nel ASA?
FlatexDegiro's revenue and profit warning has shocked shareholders. In just three trading days, it went down by about 40%. Is it now worthwhile to enter again? Analysts have a clear opinion. Can the Uniper share price halve? Analysts believe this is possible. In addition, the upcoming Extraordinary General Meeting promises to be exciting. In contrast, the media company and fintech Aspermont is doing well operationally. Therefore, analysts believe that a price multiplication is possible. The share prices of Nel and Plug Power are currently weak. Analysts are confident but currently surprisingly quiet.
Read
Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET
Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power
The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.
Read
Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET
Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions
Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.
Read
Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET
Nvidia, Meta Materials, SFC Energy - Strong signs
After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.
Read
Commented by Stefan Feulner on November 28th, 2022 | 10:41 CET
SynBiotic SE, Cardiol Therapeutics, Canopy Growth - Like hitting the jackpot
The final draft of the German government's key issues paper on the legalization of cannabis in Germany is ready, and final approval is likely to be a mere formality. For the companies concerned, this is equivalent to winning the lottery. The global cannabis market is expected to grow by 13.9% annually to USD 64.91 billion between 2022 and 2027. However, these profit increases have yet to reach the stock market. Some companies, for example, are trading below cash, while others lost more than 90% of their value in the correction that has been underway since 2019.
Read